Central Nervous System Therapeutics Market - Global Forecast 2025-2032

The central nervous system therapeutics market is evolving rapidly as new modalities, technologies, and regulatory pathways reshape treatment options for neurological disorders. Senior leaders must understand the forces driving breakthrough innovation, supply resilience, and commercial success in a sector defined by complexity and patient need.

Market Snapshot: Growth Drivers and Projections in Central Nervous System Therapeutics

The central nervous system therapeutics market grew from USD 143.11 billion in 2024 to USD 153.25 billion in 2025 and is projected to reach USD 255.04 billion by 2032, reflecting a CAGR of 7.48%. Market momentum is propelled by advances in gene therapies, monoclonal antibodies, and digital health integration, fueling a new era in patient care for conditions such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

Scope & Segmentation: Detailed Market Structure

• Indication: Alzheimer’s Disease, Attention Deficit Hyperactivity Disorder, Depression, Epilepsy, Multiple Sclerosis, Neuropathic Pain, Parkinson’s Disease, Stroke
• Mechanism of Action: Gene Therapy, Monoclonal Antibodies, Peptides, Small Molecules
• Route of Administration: Injectable, Oral, Transdermal
• End User: Clinics, Home Care, Hospitals
• Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
• Region: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe/Middle East/Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Companies Analyzed: Johnson & Johnson, Roche Holding AG, Novartis AG, Pfizer Inc., Biogen Inc., Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd.

Key Takeaways Shaping the Central Nervous System Therapeutics Market

• Gene therapies, monoclonal antibodies, and advanced peptides are transforming treatment paradigms for neurodegenerative and neuroinflammatory diseases.
• Regulatory evolution is expediting drug approvals and incentivizing real-world evidence programs, which appeal to reimbursement authorities and payers alike.
• Digital health platforms, such as remote monitoring and telemedicine, are redefining care delivery and supporting chronic neurological disease management at scale.
• Strategic partnerships—including alliances between biotech companies, contract development and manufacturing organizations, and academic institutions—are enabling faster commercialization and mitigating risk.
• Market segmentation by disease area, technology, and delivery route allows stakeholders to tailor product development and go-to-market strategies for distinct patient populations and health systems.
• Geopolitical shifts and supply chain vulnerabilities are prompting organizations to diversify sourcing and strengthen business continuity planning.

Tariff Impact: Supply Chain and Commercial Adjustments

The introduction of United States tariffs in 2025 has increased production costs for central nervous system therapeutics, impacting both supply chain dynamics and pricing strategies. Companies are actively revising sourcing models, seeking near-shoring options, and strengthening supplier diversification to counteract supply disruptions. Commercial teams are working closely with payers to demonstrate the broader value of innovative therapies amid heightened pricing scrutiny.

Methodology & Data Sources

This report uses a robust methodology grounded in primary interviews with opinion leaders and secondary reviews of scientific publications, clinical registries, and corporate disclosures. Data triangulation and cross-verification by an expert advisory panel ensure clarity, reliability, and actionable insights.

Why This Report Matters: Strategic Outcomes for Decision-Makers

• Enables evidence-based planning by providing up-to-date, segmented intelligence on therapeutic advances, regulatory trends, and regional market opportunities.
• Supports risk mitigation and supply chain optimization by reviewing tariff effects and emerging sourcing strategies relevant to global pharmaceutical leaders.
• Guides investment and partnership decisions in an environment where technology innovation, policy changes, and patient-centricity drive competitive advantage.

Conclusion

With structural innovation, regulatory progress, and shifting global dynamics, the central nervous system therapeutics market is at a pivotal juncture. Senior leaders equipped with these insights can drive informed, resilient strategies for growth and leadership in a rapidly evolving landscape.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.